Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548119 · ClinicalTrials.gov registry record · Phase 2
NeoCart Phase 2 Clinical Trial
A Phase 2 study of Articular Cartilage Damage, sponsored by Histogenics Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT00548119: Completed Phase 2 study of Articular Cartilage Damage, sponsored by Histogenics Corporation.
NCT00548119 is a Phase 2 study of Articular Cartilage Damage that has completed, run by Histogenics Corporation. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00548119, a Phase 2 study of Articular Cartilage Damage, has completed, sponsored by Histogenics Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to gather additional information regarding the performance of NeoCart to fill articular cartilage defects in the knee.
Conditions Studied
Interventions
- PROCEDURE microfracture
- BIOLOGICAL NeoCart
Study Locations (6)
New York
- Hospital for Special Surgery - New York
- Keller Army Community Hospital - West Point
California
- UCSF - San Francisco
Minnesota
- TRIA Orthopedic Center - Bloomington
North Carolina
- Duke Sports Medicine Center - Durham
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
What the finished NCT00548119 record still lists
NCT00548119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Articular Cartilage Damage appearing as the primary indexed condition, and to 2 interventions - of which microfracture is the first listed.
NCT00548119 lists 6 locations in 5 states (New York, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00548119 about?
NCT00548119 is a clinical study titled "NeoCart Phase 2 Clinical Trial". The objective of this study is to gather additional information regarding the performance of NeoCart to fill articular cartilage defects in the knee.
What is the current status of trial NCT00548119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-12. Estimated completion is 2014-03.
What conditions does trial NCT00548119 study?
This clinical trial studies the following conditions: Articular Cartilage Damage.
What interventions are being tested in trial NCT00548119?
The interventions under investigation include: microfracture (PROCEDURE), NeoCart (BIOLOGICAL).
Who is sponsoring clinical trial NCT00548119?
This trial is sponsored by Histogenics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00548119 being conducted?
This trial has 6 study locations across California, Minnesota, New York, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00548119's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia